Clinical trials: Pancreatic Fibrosis
Cystic Fibrosis
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation
The purpose of this study was to evaluate the safety of ivacaftor treatment, and PK of ivacaftor and metabolites in participants with cystic fibrosis (CF) who are <24 months of age at treatment initiation and have an…
- Trial name
- NCT02725567
- Testing
- IVA
- Where
- 23 sites in United States, Australia and 3 more
- Volunteers
- 57 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Neurodevelopmental Disorders, Cystic Fibrosis
Neurodevelopmental Assessment of Infants With Cystic Fibrosis
Infants included in the study will be divided into two groups as healthy infants and cystic fibrosis infants . Demographic, natal and postnatal information of the infants will be available from patient files.
- Trial name
- NCT03577756
- Testing
- Neurodevelopmental assessments
- Where
- Turkey (Türkiye)
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Hacettepe University
Cystic Fibrosis, Cystic Fibrosis-related Diabetes
The Effects of a Low Glycemic Load Diet on Dysglycemia and Body Composition in Adults With Cystic Fibrosis-Related Diabetes
This study will evalute the effect of a low glycemic load (LGL diet on dysglycemia, insulin requirements, DXA-derived body composition, gastrointestinal symptoms and quality of life measures in adults with cystic fibrosis-related…
- Conditions
- Cystic Fibrosis, Cystic Fibrosis-related Diabetes, Cystic Fibrosis With Intestinal Manifestations
- Trial name
- DINE (NCT05723445)
- Testing
- Low Glycemic Load Diet
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Rhode Island Hospital
Cystic Fibrosis
The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis
This study is examining the effect of hypertonic saline compared to placebo on the Lung Clearance Index in Cystic Fibrosis patients.
- Trial name
- NCT00635141
- Testing
- hypertonic saline (7 %) and isotonic saline (0.9%)
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- The Hospital for Sick Children
Cystic Fibrosis (CF)
Machine Learning Prediction of Pulmonary Function in Children With Cystic Fibrosis
Cystic fibrosis is a multisystem genetic disorder characterized by progressive pulmonary impairment and extrapulmonary limitations.
- Trial name
- NCT07770854
- Testing
- Archived Multidimensional Clinical and Functional Assessment Data
- Where
- Turkey (Türkiye)
- Volunteers
- 31 people
- Sponsor
- Gazi University
Cystic Fibrosis
DNA Methylation and Lung Disease in Cystic Fibrosis
Lung disease progression is variable among cystic fibrosis (CF) patients and depends on DNA mutations in the CFTR gene, polymorphic variations in disease-modifier genes and environmental exposure.
- Trial name
- METHYLCF (NCT02884622)
- Testing
- nasal epithelial, Blood sampling
- Where
- France
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Cystic Fibrosis
Safety and Tolerability Study of Liquid Alpha1 Proteinase Inhibitor (API) in Subjects With Cystic Fibrosis
Study to assess safety and tolerability of a single dose of study-drug administered to Cystic Fibrosis (CF) patients.
- Trial name
- NCT01347190
- Testing
- CR002 Liquid API
- Where
- 11 sites in Bulgaria, Hungary and 2 more
- Volunteers
- 25 people
- Sponsor
- CSL Behring
Cystic Fibrosis
Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic Fibrosis
Cystic fibrosis is an inherited disorder leading to chronic pulmonary inflammation and infection. A majority of people with cystic fibrosis have large quantities of bacteria residing in their lungs.
- Trial name
- PIPE-CF (NCT01694069)
- Testing
- Piperacillin-tazobactam combination product
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- West Virginia University
Cystic Fibrosis
A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele
This is a Phase 2 open label study to evaluate the safety, tolerability, PK, and PD of multiple dose levels of SC administered ELX-02 with and without ivacaftor in patients with CF with at least one G542X allele or phenotypically…
- Trial name
- NCT04126473
- Testing
- ELX-02, Ivacaftor
- Where
- 9 sites in Australia, Germany and 1 more
- Volunteers
- 17 people
- Sponsor
- Eloxx Pharmaceuticals, Inc.
Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
The purpose of this study is to look at pulmonary exacerbations in people with cystic fibrosis (CF) that need to be treated with antibiotics given through a tube inserted into a vein (intravenous or IV).
- Trial name
- STOP360AG (NCT05548283)
- Testing
- Beta-lactam antibiotic, Aminoglycoside
- Where
- 60 sites in United States, Canada
- Volunteers
- 730 people
- Sponsor
- Chris Goss
Pancreatic Exocrine Insufficiency
Evaluation of Safety and Tolerability of Creon Micro in Children Younger Than Four Years With Pancreatic Exocrine Insufficiency
The purpose of this study is to evaluate the safety and tolerability of Creon micro in children younger than four years with pancreatic exocrine insufficiency.
- Trial name
- NCT01747330
- Testing
- Pancreatin
- Where
- 9 sites in Russia
- Volunteers
- 40 people
- Sponsor
- Abbott Products
Cystic Fibrosis
Gastrointestinal Study at Orkambi Therapy in CF Patients
Ivacaftor caused a significance increase in weight in patients carrying the G551D mutation and the etiology of this has largely remained unknown but may be due to improved function of the gastrointestinal tract.
- Trial name
- NCT03859531
- Where
- Sweden
- Volunteers
- 20 people
- Sponsor
- Karolinska University Hospital
Cystic Fibrosis
FDG-PET Imaging in Young Cystic Fibrosis Patients
The purpose of this research is to determine how a person's lungs will uptake [18F]fluorodeoxyglucose (FDG), as measured with positron emission tomography (PET) scanning in young cystic fibrosis (CF) patients.
- Trial name
- NCT00846053
- Testing
- FDG-PET
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Washington University School of Medicine
Cystic Fibrosis
Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic Fibrosis
The purpose of this study is to determine antimycobacterial drug pharmacokinetics (PK) and pharmacodynamics (PD) in patients with cystic fibrosis (CF) to improve treatment of nontuberculous mycobacterial (NTM) lung disease.
- Trial name
- NCT02372383
- Testing
- Ethambutol, Rifampin, Azithromycin
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
CYSTIC FIBROSIS
Effect of Lactobacillus Reuteri in Cystic Fibrosis
The purpose of this study is to evaluate in patients with cystic fibrosis the effect of Lactobacillus Reuteri (LR) on the rate of respiratory exacerbations and of the infections of both upper respiratory and gastrointestinal…
- Trial name
- NCT01737983
- Testing
- Lactobacillus reuteri
- Where
- Italy
- Volunteers
- 61 people
- Sponsor
- Azienda Policlinico Umberto I
Cystic Fibrosis
Study to Assess Efficacy of AZD1236 in Patients With Cystic Fibrosis
The purpose of this study is to determine the effect of AZD1236 in patients with cystic fibrosis (CF) on inflammatory biomarkers in induced sputum, after a treatment period of 4 weeks.
- Trial name
- CYBER (NCT00812045)
- Testing
- AZD1236
- Where
- 10 sites in Canada, Netherlands and 2 more
- Volunteers
- 44 people
- Sponsor
- AstraZeneca
Ototoxicity
SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity
The primary objective of this study is to determine the safety and efficacy of SPI-1005 treatment in CF patients with active pulmonary exacerbation that are receiving an IV course of tobramycin, determined by comparing hearing…
- Trial name
- NCT02819856
- Testing
- SPI-1005 Ebselen 200mg Capsule x1, SPI-1005 Ebselen 200mg Capsule x2, SPI-1005 Ebselen 200mg Capsule x3
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Sound Pharmaceuticals, Incorporated
Cystic Fibrosis Pulmonary Exacerbation
Pharmacokinetic Study of Extended Infusion Meropenem in Adult Cystic Fibrosis Patients
Meropenem is an intravenous antibiotic commonly used to treat acute exacerbation of respiratory infections in cystic fibrosis. The research study aims to determine if a different method of infusing the drug over 3 hours or…
- Trial name
- NCT01158937
- Testing
- Meropenem Infusion
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- Unity Health Toronto
Cystic Fibrosis
Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy
This study evaluated the long-term safety, efficacy, and pharmacodynamics of elexacaftor (ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are…
- Trial name
- NCT04058366
- Testing
- ELX/TEZ/IVA, IVA
- Where
- 84 sites in United States, Australia and 10 more
- Volunteers
- 251 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cystic Fibrosis
A Coaching Intervention to Young Adults With Cystic Fibrosis
The treatment burden for patients with cystic fibrosis (CF) is significant and poor adherence has been well-documented. The investigators hypothesize that a coaching intervention will empower young adults with CF to manage their…
- Trial name
- NCT02110914
- Testing
- Coaching
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.